Literature DB >> 16715226

[Pancreas. Part II: Tumors].

W Schima1, A Ba-Ssalamah, C Plank, C Kulinna-Cosentini, R Prokesch, B Tribl, T Sautner, B Niederle.   

Abstract

Adenocarcinoma is the most common malignant pancreatic tumor, affecting the head in 60-70% of cases. By the time of diagnosis, approximately 80% of tumors are unresectable. Helical CT is very effective in detection and staging of adenocarcinoma, with a sensitivity of 76-92% for detection and an accuracy of 80-90% for staging, but it has limitations in the detection of small cancers (< or =2 cm). Multidetector CT (MDCT) has brought substantial improvements with its inherent 3D imaging capability. Mangafodipir-enhanced MRI is a problem-solving tool in the depiction of small cancers following an equivocal CT imaging result. Gadolinium-enhanced 3D gradient-echo MRI is helpful in the assessment of vascular invasion of cancer and in determining the etiology of cystic lesions. Serous cystadenoma is benign, has a lobulated contour and contains innumerable small cysts of 0.1-2 cm in diameter. Mucinous cystic neoplasms are unilocular or multilocular (fewer than six cysts), and the cyst diameter exceeds 2 cm. The presence of solid nodular components should alert the radiologist to suspect cystadenocarcinoma. Neuroendocrine tumors are mostly hypervascular. Diagnosis of insulinoma is a challenge: they are <2 cm in 90% of cases and mostly hypervascular at CT or MRI. A combination of contrast-enhanced MDCT, MRI, endosonography, and/or somatostatin receptor scintigraphy is used to detect these small tumors. This review summarizes the imaging features of the most common pancreatic tumors and discusses the limitations of CT, MRI and endosonography.

Entities:  

Mesh:

Year:  2006        PMID: 16715226     DOI: 10.1007/s00117-006-1372-9

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  63 in total

Review 1.  [Imaging of neuroendocrine tumors of the pancreas].

Authors:  C Vick; C J Zech; S Höpfner; T Waggershauser; M Reiser
Journal:  Radiologe       Date:  2003-04       Impact factor: 0.635

2.  Serous cystadenoma of the pancreas: tumor growth rates and recommendations for treatment.

Authors:  Jennifer F Tseng; Andrew L Warshaw; Dushyant V Sahani; Gregory Y Lauwers; David W Rattner; Carlos Fernandez-del Castillo
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

Review 3.  Metastases to the pancreas.

Authors:  E M Merkle; T Boaz; O Kolokythas; J R Haaga; J S Lewin; H J Brambs
Journal:  Br J Radiol       Date:  1998-11       Impact factor: 3.039

4.  Comparison of helical CT and MR imaging in detecting and staging small pancreatic adenocarcinoma.

Authors:  H Irie; H Honda; K Kaneko; T Kuroiwa; K Yoshimitsu; K Masuda
Journal:  Abdom Imaging       Date:  1997 Jul-Aug

5.  Ultrafast magnetic resonance imaging improves the staging of pancreatic tumors.

Authors:  M Trede; B Rumstadt; K Wendl; J Gaa; K Tesdal; K J Lehmann; H J Meier-Willersen; P Pescatore; J Schmoll
Journal:  Ann Surg       Date:  1997-10       Impact factor: 12.969

6.  Pancreatic malignancy: value of arterial, pancreatic, and hepatic phase imaging with multi-detector row CT.

Authors:  Joel G Fletcher; Maurits J Wiersema; Michael A Farrell; Jeff L Fidler; Lawrence J Burgart; Takashi Koyama; C Daniel Johnson; David H Stephens; Ellen M Ward; W Scott Harmsen
Journal:  Radiology       Date:  2003-10       Impact factor: 11.105

7.  Pancreatic tissue sampling guided by EUS, CT/US, and surgery: a comparison of sensitivity and specificity.

Authors:  J Shawn Mallery; Barbara A Centeno; Peter F Hahn; YuChiao Chang; Andrew L Warshaw; William R Brugge
Journal:  Gastrointest Endosc       Date:  2002-08       Impact factor: 9.427

8.  Pancreatic tumours in patients with previous malignancy.

Authors:  R Whittington; D J Moylan; R R Dobelbower; S Kramer
Journal:  Clin Radiol       Date:  1982-05-03       Impact factor: 2.350

9.  Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT.

Authors:  Wolfgang Schima; Reinhold Függer; Ewald Schober; Claudia Oettl; Peter Wamser; Florian Grabenwöger; J Mark Ryan; Gottfried Novacek
Journal:  AJR Am J Roentgenol       Date:  2002-09       Impact factor: 3.959

10.  Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer.

Authors:  John DeWitt; Benedict Devereaux; Melissa Chriswell; Kathleen McGreevy; Thomas Howard; Thomas F Imperiale; Donato Ciaccia; Kathleen A Lane; Dean Maglinte; Kenyon Kopecky; Julia LeBlanc; Lee McHenry; James Madura; Alex Aisen; Harvey Cramer; Oscar Cummings; Stuart Sherman
Journal:  Ann Intern Med       Date:  2004-11-16       Impact factor: 25.391

View more
  6 in total

Review 1.  [Indications for magnetic resonance imaging in Internal Medicine. When do we really need this technology?].

Authors:  A G Schreyer; K Debl; H Herfarth
Journal:  Internist (Berl)       Date:  2010-04       Impact factor: 0.743

Review 2.  Pancreatic adenocarcinoma.

Authors:  Wolfgang Schima; Ahmed Ba-Ssalamah; Claus Kölblinger; Christiane Kulinna-Cosentini; Andreas Puespoek; Peter Götzinger
Journal:  Eur Radiol       Date:  2006-10-05       Impact factor: 5.315

3.  Value of three-dimensional reconstructions in pancreatic carcinoma using multidetector CT: initial results.

Authors:  Miriam Klauss; Max Schöbinger; Ivo Wolf; Jens Werner; Hans-Peter Meinzer; Hans-Ulrich Kauczor; Lars Grenacher
Journal:  World J Gastroenterol       Date:  2009-12-14       Impact factor: 5.742

Review 4.  [Computed tomography of pancreatic tumors].

Authors:  L Grenacher; M Klauss
Journal:  Radiologe       Date:  2009-02       Impact factor: 0.635

5.  [Tumor-like lesion of the pancreas in chronic pancreatitis : imaging characteristics of computed tomography].

Authors:  C J Zech; C Bruns; M F Reiser; K A Herrmann
Journal:  Radiologe       Date:  2008-08       Impact factor: 0.635

Review 6.  MRI of the pancreas: tumours and tumour-simulating processes.

Authors:  Wolfgang Schima
Journal:  Cancer Imaging       Date:  2006-12-20       Impact factor: 3.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.